Sign in
Taking people in United StatesPhase 2

Probenecid Administration for Alcohol Craving and Consumption

Key facts

Who runs it
Brown University
Where
Providence, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
14 Mar 2026
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Probenecid Oral Tablet
  • Placebo Oral Tablet
Record updated
17 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • • Male or female, ≥18 years; women >7 drinks/week; men >14 drinks/week; meet moderate to severe AUD score for DSM-5 criteria; Breath Alcohol Content (BrAC)=0.00 at each visit; in good health as confirmed by medical history, physical examination and lab tests; willing to adhere to the study procedures; understand informed consent and questionnaires in English at an 8th grade level

Who cannot take part

  • • Women who are breastfeeding or positive urine test for pregnancy; clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin >150% of the upper normal limit, ALT/AST >300% the UNL, creatinine clearance ≤60 dl/min; meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses; medications that reduce alcohol consumption (naltrexone, disulfiram); use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration); history of suicide attempts in the last three years; current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline; current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline; current use of medications that may interact with probenecid; history of hypersensitivity to sulfa drugs

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alcohol use disorder or alcohol consumption or craving

This trial is currently available in United States.

  • Brown UniversityProvidence, United StatesContact: Brian Gully, MATaking people

About the trial

What the trial wants to find out

This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.

The 2 groups in the trial

  • Study drugTreatment being tested

    Probenecid 2gr oral

    Treatment: Probenecid Oral Tablet

  • PlaceboPlacebo, for comparison

    Placebo inactive

    Treatment: Placebo Oral Tablet

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Probenecid, Pannexin 1 Channels for Alcohol Use Disorder
Criteria questions
Built from NCT07118618, who can take part
Record updated
17 March 2026